ALXO

ALX Oncology Holdings Inc. | Cotação de Ações

Última atualização31/01/2025, 18:00:02

PreçoUS$ 1,46

Variação (dia)US$ 0,16 (11.88%)▲

Min. 52 SemanasUS$ 1,19

Máx. 52 SemanasUS$ 17,83

Capitalização de mercado--

Endereço: 323 Allerton Avenue, South San Francisco, CA, 94080

Telefone: 650 466 7125

Funcionários: 89

ALX Oncology Holdings Inc.ALXO

US$ 1,46

+ 0,15512%

31/01/2025 18:00:02

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 1,46

Valor de mercado--

AberturaUS$ 1,44

Preço máximoUS$ 1,46

Preço mínimoUS$ 1,33

VolumeUS$ 1 mi

Fechamento anteriorUS$ 1,31

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Ações relacionadas

Generation Bio Co.

GBIO ▲0.00% | US$ 0,95

Nkarta, Inc.

NKTX ▼0.02% | US$ 2,47

IGM Biosciences, Inc.

IGMS ▼0.06% | US$ 1,77

Annexon, Inc.

ANNX ▲0.09% | US$ 4,20

Zentalis Pharmaceuticals, Inc.

ZNTL ▼0.15% | US$ 2,24

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Encontre respostas para suas dúvidas sobre investimentos em nossa seção de Perguntas Frequentes (FAQ)

Acesse a seção de Perguntas Frequentes da brapi para esclarecer dúvidas sobre investimentos. Nossa FAQ fornece informações concisas, abordando tópicos relevantes para investidores, contribuindo para uma compreensão mais clara do mercado financeiro.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.